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Abstract
Objectives. Prevalence of SLE varies among studies, being influenced by study design, geographical area and
ethnicity. Data about the prevalence of SLE in Spain are scarce. In the EPISER2016 study, promoted by the
Spanish Society of Rheumatology, the prevalence estimate of SLE in the general adult population in Spain has
been updated and its association with sociodemographic, anthropometric and lifestyle variables has been explored.
Methods. Population-based multicentre cross-sectional study, with multistage stratified and cluster random sam-
pling. Participants were contacted by telephone to carry out a questionnaire for the screening of SLE. Investigating
rheumatologists evaluated positive results (review of medical records and/or telephone interview, with medical visit
if needed) to confirm the diagnosis. To calculate the prevalence and its 95% CI, the sample design was taken into
account and weighing was calculated considering age, sex and geographic origin. Multivariate logistic regression
models were defined to analyse which sociodemographic, anthropometric and lifestyle variables included in the
telephone questionnaire were associated with the presence of SLE.
Results. 4916 subjects aged 20 years or over were included. 16.52% (812/4916) had a positive screening result
for SLE. 12 cases of SLE were detected. The estimated prevalence was 0.21% (95% CI: 0.11, 0.40). SLE was
more prevalent in the rural municipalities, with an odds ratio (OR) ¼ 4.041 (95% CI: 1.216, 13.424).
Conclusion. The estimated prevalence of SLE in Spain is higher than that described in most international epi-
demiological studies, but lower than that observed in ethnic minorities in the United States or the United Kingdom.
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. EPISER2016 has shown an SLE prevalence of 210 cases per 100 000 inhabitants (95% CI: 110, 400).
. SLE prevalence is higher than that described in most international epidemiological studies.
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Introduction
SLE is a multi-systemic autoimmune disease with a
complex and diverse nature in its clinical presentation. It
occurs more frequently in young, fertile women and can
appear in all ethnicities.
Prevalence of SLE varies among studies, being influ-
enced by study design, geographical area and ethnicity.
In the USA, a national population-based study with data
from the Third National Health and Nutrition Examination
Survey (NHANES III) estimated a prevalence of 241
cases/100 000 adults, based on self-reported physician-
diagnosed SLE [1]. In a retrospective study in the
UK, based on a longitudinal database of general prac-
tice records, it was 97 cases/100 000, being as high
as 517.5/100 000 for people of Black Caribbean ethni-
city [2].
Data published in literature about the prevalence of
SLE in Spain are scarce and most of them are limited to
very specific geographic areas [3, 4]. In 2000, the
Spanish Society of Rheumatology (SER), through the
EPISER2000 study, estimated a prevalence of SLE in
the adult Spanish population of 91 cases per 100 000
inhabitants (95% CI: 30, 390) [5].
In the EPISER2016 study, a reissue of EPISER2000
promoted by the SER, the prevalence data of SLE in the
general adult population in Spain has been updated,
seeking to improve precision by increasing the sample
size. Also, the extent to which different sociodemo-
graphic, anthropometric and lifestyle variables may influ-
ence this prevalence has been explored.
Methods
The aims, methods and sample characteristics of the
EPISER2016 study have been previously described
[6, 7]. Briefly explained, it is a population-based, multi-
center, cross-sectional study to estimate the prevalence
of the major rheumatic diseases (RA; SLE; symptomatic
osteoartrhritis of the hand, knee, hip, cervical and lum-
bar spine; fibromyalgia; ankylosing spondylitis; psoriatic
arthritis; Sjögren’s syndrome; gout; and symptomatic
osteoporotic fracture) in the adult population in Spain.
As EPISER2016 included various diseases, for sample
size calculation we focused on RA and PsA prevalence
(election by convenience, based on the previous
EPISER2000). Assuming a Poisson distribution, a sam-
ple comprising 4000 individuals would enable to obtain
a 95% CI of 0.30, 0.77 for a prevalence of 0.5%
(expected for RA) and of 0.14–0.54 for a prevalence of
0.3% (expected for psoriatic arthritis). Assuming 20% of
missing values, it was considered necessary to include
around 5000 individuals [6, 7].
Subjects were randomly selected by means of multi-
stage stratified (strata based on rural/urban municipal-
ities, sex and age) cluster sampling, who resided in 78
municipalities randomly selected throughout all the au-
tonomous communities in Spain. In case of non-
answered phone calls, a minimum of six attempts were
made in different time frames. If after these attempts
there was no answer or the subject refused to partici-
pate, another phone number within the same municipal-
ity was randomly selected. Similarly, if any of the
randomized municipalities were not representative of the
autonomous community, mainly because of its sociode-
mographic characteristics such as a high percentage of
foreigners or second homes, it was replaced by another
randomly selected municipality of the same autonomous
community [7].
In all locations, the participants were contacted by
using random digit dialling and a Computer Assisted
Telephone Interviewing system (CATI) to conduct a
questionnaire for the screening of the diseases under
study. The survey was mostly performed via landlines,
but in order to facilitate access to younger patients and
expand the registry, we have incorporated mobile
phones since March 2017, which represent 20.3% of
the final sample. This figure reflects the proportion of
homes in Spain that relied solely on a mobile telephone
connection [7]. Both for the randomized selection of tel-
ephones in each municipality as well as for conducting
the initial screening interviews, an external company
working in sociological studies was involved, with ex-
perience in the area of health and call centre services
(Ipsos Espa~na).
The screening considered two complementary paths.
First, participants were asked if they had already been
diagnosed with any of the diseases under study. Then,
a screening was carried out based on symptoms (see
Supplementary Material, section Questionnaire of the
call centre for symptom-based screening, available
at Rheumatology online, for SLE symptom-based
screening).
If participants reported to be diagnosed with any of
the diseases under study, they were requested to con-
sent for the rheumatologists who were participating as
researchers at the municipality’s referral hospital to con-
firm this diagnosis in their clinical records. Individuals
who did not mention that they were previously diag-
nosed, but who presented positive results in the
symptom-based screening, were again interviewed via
telephone by the investigating rheumatologist to assess
the suspicion by carrying out a second questionnaire
(see Supplementary Material, section Telephone ques-
tionnaire used by rheumatologist to study the suspicion,
available at Rheumatology online, for the SLE question-
naire). If the suspicion was maintained, a medical ap-
pointment was arranged to complete the process of
diagnosis confirmation (physical examination and com-
plementary tests), according to the 1982 SLE ACR crite-
ria (these were used in the EPISER2000) and the 2012
SLICC criteria [8, 9].
These criteria were used in the confirmation of cases
that were not diagnosed before the study. For subjects
who were already diagnosed beforehand, it was not ac-
tively required to look over their clinical records to com-
ply with the criteria; clearly identified diagnoses were
accepted, regardless of the criteria used.
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Cases in which the subject completed the call centre
interview with a positive result for the screening of SLE
and the rheumatologist could not confirm or rule out the
diagnosis were considered missing.
The oral informed consent of all subjects was
requested upon first telephone contact. Additionally,
written informed consent was requested for all those
who went to the participating centres for a physical
examination and complementary testing. The study was
approved by the Clinical Research Ethics Committee
(CREC) of Hospital Universitario de Canarias (Acta 12/
2016), which acted as the CREC of reference, and the
CRECs of the participating centres that so required it.
Patient and public involvement (PPI)
There were no funds or time allocated for PPI so we
were unable to involve patients. We have invited
patients to help us develop our dissemination strategy.
Statistical analysis
To calculate the prevalence and its 95% CI, the sample
design was taken into account. The weights were calcu-
lated depending on the selection probability in each of
the stages of the sampling, taking as a reference the
distribution of the population in Spain according to cen-
sus data from the Spanish Institute of Statistics. This
weighing was carried out considering age, sex and geo-
graphic origin (three zones were defined: North [Galicia
þ Asturias þ Cantabria þ Basque Country þ Navarre þ
La Rioja], Mediterranean and the Canary Islands
[Catalonia þ Valencian Community þ Balearic Islands þ
Murcia þ Andalusia þ Canary Islands] and Centre
[Community of Madrid þ Castile and León þ Aragón þ
Castile-La Mancha þ Extremadura]).
Finally, predictive models were defined to analyse
which sociodemographic, anthropometric and lifestyle
variables included in the first phone questionnaire were
associated with the presence of SLE. To that end, first,
bivariate analysis was carried out on the association of
the disease to each of the variables and then binary lo-
gistic regression models were constructed using those
variables with a P-value of <0.2 in bivariate analysis
(age and sex were included in the model, regardless of
the P-value in bivariate analysis). Statistical significance
was defined as P < 0.05. The analyses were performed
using IBM SPSS Statistics v22.
Results
A total of 84 098 different phone numbers were dialled
from November 2016 to October 2017. Of these, 50 170
were wrong numbers or were unanswered; 28 784 indi-
viduals refused to participate (27 895 or 96.9% from the
very beginning of the interview); in all 5144 interviews
were completed (thus, the response rate once the sub-
ject had answered the phone call was 15.2%). After
eliminating duplicate interviews or excess numbers from
certain sample strata, 4916 individuals were included in
the final analysis. Baseline characteristics of the sample
and a comparison with the general population aged
20 years or older in Spain (reference population in
EPISER2016) have been published in detail elsewhere
[7].
After the first phone call, 16.52% (812/4916) of indi-
viduals had a positive screening result for SLE. Of these,
6.77% (55/812) were missing. Twelve cases of SLE (10
women, 2 men) were detected, of which 91.67% (11/12)
had been diagnosed prior to the EPISER2016 study.
The estimated prevalence was 0.21% (95% CI: 0.11,
0.40).
The positive predictive value of the SLE screening
questionnaire carried out by the call centre was 1.45%
(11 cases of SLE among the 757 subjects with positive
screening who completed the study). The remaining
case, not detected in the SLE screening, was a 37 year-
old women, who had been diagnosed prior to the study
and with a negative screening result for all the diseases
included in the EPISER2016 study, except for the symp-
tomatic screening for Sjögren’s syndrome.
Negative predictive value among those with positive
screening result for any of the other rheumatic diseases
(not SLE) included in EPISER2016 was 99.95%
(n¼1862/1863). In a pre-planned substudy on 209 sub-
jects randomly selected among those with a negative
screening result for all the diseases, no cases of SLE
were detected.
Bivariate and multivariate analysis
Bivariate and multivariate analyses were limited by the
low number of SLE cases in the sample. Table 1 shows
the P-values of the associations found in bivariate ana-
lysis between the presence of SLE and sociodemo-
graphic, lifestyle and anthropometric variables included
in the questionnaire carried out by the call centre.
Table 2 includes the results of multivariate analysis.
The type of municipality showed a statistically significant
association with the presence of SLE (P ¼ 0.023), being
more prevalent in the rural municipalities, with an odds
ratio (OR) ¼ 4.041 (95% CI: 1.216, 13.424).
Discussion
The prevalence of SLE varies between the different
geographical areas of the world that have been
studied. In Spain, Gómez et al. described a prevalence
in 2003 of 31.7 cases per 100 000 inhabitants (95% CI:
28.3, 35.0) [4]. Alonso et al. carried out an epidemio-
logical study in 2006, describing a prevalence of 17.5
cases per 100 000 inhabitants (95% CI: 12.6, 24.1) [3],
slightly lower than the prevalence cited in the study by
Gómez et al. Both studies accounted for cases that
were already diagnosed, detected in the review of
medical records, and are limited to parts of north-
western Spain.
The EPISER2000 study (carried out in 1998–99) found
a prevalence of SLE in the adult Spanish population of
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91 cases per 100 000 inhabitants (95% CI: 30, 390),
markedly higher than the previously mentioned data
from our country [5]. The EPISER2000 was based on a
relatively small sample size, due to which its increase in
the EPISER2016 makes its results more precise.
The estimated prevalence of SLE in the EPISER2016
study is 210 cases per 100 000 inhabitants (95% CI:
110, 400). In general, this prevalence is higher than that
described in other geographical areas, with the excep-
tion of that obtained in a North American study [1]. This
population-based study used the data from a national
survey in the first half of the 1990s, the Third National
Health and Nutrition Examination Survey (NHANES III),
to calculate the prevalence of SLE in the United States,
based on self-reported physician-diagnosed cases. The
estimated prevalence was 241 cases per 100 000 adults
aged 17 years or older (95% CI: 130, 352), which fell to
a value of 53.6 per 100 000 (95% CI: 12.2, 95.0) if fur-
thermore the criterion was added to take into account
the prescription of antimalarials, glucocorticoids or
immunosuppressants.
In the United Kingdom, a retrospective study used a
Primary Healthcare longitudinal database, the Clinical
Practice Research Datalink (CPRD), considered to be
representative of the population of the United Kingdom,
to calculate the prevalence of SLE in the period from
1999 to 2012, stratified by year, age group, sex, region
and ethnicity [2]. The authors found a lower prevalence
than observed in the EPISER2016, but higher than that
described in most published series in literature [10]. The
prevalence in this study increased throughout time, from
64.9 cases per 100 000 inhabitants (95% CI: 62.0, 67.9)
in 1999 to 97.0 per 100 000 (95% CI: 94.1, 99.9) in
2012. For certain ethnic groups, a prevalence of SLE
was observed that was even higher than that described
in the EPISER2016. Thus, for the black population of
Caribbean origin, it was 517.5 cases per 100 000 inhabi-
tants in 2012 (95% CI: 398.5 660.8), and for the black
population of non-Caribbean or African origin, 325.5
cases per 100 000 inhabitants (95% CI: 231.4, 496.2)
[2].
TABLE 1 Association between the presence of SLE and












Sex, female 83.3% 54.2% 0.043









Birth abroad 8.3% 6.9% 0.58





Never smoker 50.0% 49.1%










Obesity (BMI 30) 18.2% 14.8%
TABLE 2 Variables associated with the presence of SLE. Multivariate analysis
Variables OR 95% CI P-value
Lower Upper
Age From 20 to 39a
From 40 to 59 1.449 0.343 6.118 0.61
60 0.332 0.030 3.733 0.37
Sex Female 3.498 0.710 17.246 0.12
Rural/urban Rural 4.041 1.216 13.424 0.023
Level of studies Basica
Intermediate 2.532 0.596 10.756 0.21
Higher 0.585 0.090 3.805 0.58
BMI Normal weighta
Underweight 6.642 0.714 61.792 0.096
Overweight 0.833 0.194 3.584 0.80
Obese 1.518 0.286 8.065 0.62
aCategory of reference.
OR: odds ratio.
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Of particular interest is a Greek community-based
study, in which using a method of active detection of SLE
cases from different sources (they only took into account
previously diagnosed cases), they observed a steady in-
crease in the crude prevalence of SLE. Thus, in 1999 it
was 22 (95% CI: 18, 26) cases per 100 000 inhabitants
aged 15 years or older, against 143 (95% CI: 133, 154) in
2013 [11]. This latter prevalence is closer to that esti-
mated in our study, considering that the Greek study
included people between 15 and 20 years old and this
age group would have lower prevalence rates [12, 13].
The symptom-based screening enabled detecting 1 of
the 12 cases in the EPISER2016 study that was not pre-
viously diagnosed. This fact would contribute to explain
part of the higher prevalence of SLE compared with
other studies based on the review of various databases.
According to published data, annual frequency of hos-
pital admissions in patients with SLE in Spain (assessed
as the number of hospital admissions divided by the
number of patients with SLE) was around 9.5% in 2015
[14]. In the Registry of Hospital Discharges of the
National Health System, which includes 93% of hospital
discharges documented in Spanish hospitals (https://pes
tadistico.inteligenciadegestion.mscbs.es/publicoSNS/Co
mun/ArbolNodos.aspx? idNodo¼6383) that year, there
were 6744 admissions with one diagnosis code corre-
sponding to SLE (710.0 in the ICD-9-CM) in the general
population aged 20 years or older. Based on the SLE
prevalence estimated by EPISER2016 (0.21%), there
should have been 78 644 SLE patients aged 20 years or
older in Spain (37 449 402 global population in 2015). If
the annual frequency of hospital admissions in patients
with SLE was 9.5%, as previously mentioned, and
according to EPISER2016 data, there should have been
7471 hospital admissions in Spain, a figure that is close
to 6744. These data suggest that the prevalence of SLE
as detected by EPISER2016 does, in fact, reflect the
reality of this disease in Spain.
EPISER2016 was designed to determine the global
prevalence of several rheumatic disease in Spain. The
analysis of the association with sociodemographic, an-
thropometric and lifestyle variables was a secondary ob-
jective and for pathologies with a low prevalence, such
as RA, Sjögren’s syndrome or SLE, the statistical power
for this analysis is very limited. Taking into account this
fact for the interpretation, we observed the greatest fre-
quency of the disease in women, in line with all pub-
lished series in literature; the magnitude of the
association in the multivariate analysis would be in the
lower part of the range reported in the literature (a
prevalence ratio as low as 3.6:1 has been reported in
Germany) [10, 12, 15]. We also observed that SLE is
more prevalent in Spain in rural areas in comparison to
urban areas, with an OR of 4.041, even though due to
the very few cases of SLE the estimate would be quite
imprecise (95% CI: 1.216, 13.424). There is little data in
literature in this regard but, in general, contrary to our
study, it is agreed that SLE is more prevalent in urban
than in rural regions [11, 16, 17]. In the previously
mentioned Greek study, the prevalence was 165 per
100 000 in urban regions vs 123 per 100 000 in rural
regions (P < 0.001) [11]. It is difficult to interpret these
discordant results, which deserve a more detailed ana-
lysis in future epidemiological studies.
As a limitation of the study, though the sample size
was increased more than double in comparison with
EPISER2000, the low prevalence of SLE entails relatively
wide CI. Nevertheless, this is similar to that estimated in
the USA and its lower limit is above the higher limit of
CIs in most recent studies from other countries [1, 15].
Among the strengths of our study, it should be high-
lighted that criteria for SLE symptomatic screening used
in the first phone call allowed a very high sensitivity.
Telephone surveys have become an accepted method
for prevalence studies on rheumatic diseases [18–21].
The response rate for calls in EPISER2016 was 15.2%,
which could be interpreted as a possible source of bias.
However, this response rate is consistent with other re-
cent population-based telephone surveys for prevalence
analyses and was possibly lower compared with other
studies due to the demanding sampling requirements
(strata based on rural/urban, sex and decades of age)
[22–25]. In the last decades, epidemiological studies in
developed countries have been hampered by a marked
decline in participation levels, and thus their importance
in terms of the validity of estimates remains an open
question. Different reports concerning this issue have
concluded that a low response rate, in and of itself,
does not necessarily induce bias when the reasons for
non-participation are unrelated to the variables of inter-
est in the study [22, 26–28]. In this regard, self-reported
data on osteoarthritis, chronic cervical pain and chronic
lumbar pain available from the 2017 National Health
Survey of Spain, a survey boasting rigorous sampling
procedures, are similar to those that were initially self-
reported by the subjects in EPISER2016 (20, 6% vs 18,
4%; 17, 4% vs 13, 5%; 21, 7% vs 18, 4%, respectively)
[7, 29]. This would support the view that the possible
reasons for refusing to participate in EPISER2016 are
not associated with its primary objective, therefore indi-
cating that the participation rate is unlikely to be a sig-
nificant source of bias in our study.
In conclusion, the EPISER2016 study has shown a
SLE prevalence in Spain of 210 cases per 100 000
inhabitants (95% CI: 110, 400). This prevalence is higher
than that described in most international epidemiological
studies, but lower than that observed in different ethnic
minorities in the United States or in the United Kingdom.
We observed a higher prevalence of SLE in rural than in
urban environments. This finding is contrary to that usu-
ally described in literature in this regard and deserves to
be more specifically evaluated in upcoming epidemio-
logical studies.
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